Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib + NSAI in advanced breast cancer (proMONARCH)
NCT03988114Phase 4Withdrawn
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2019
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 4, open-label, single-arm trial of abemaciclib in breast cancer, sponsored by Eli Lilly and Company. Primary endpoints: Progression Free Survival up to 26 months and Objective Response Rate up to 26 months. Planned start Sep 2019; status: withdrawn.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03988114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03988114.